Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK, Engelhard HH, Lakka SS. · 2020
Read Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. by Ahir BK, Engelhard HH, Lakka SS. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7170819.txt.
Introduction
Ahir and co-authors review how glioblastoma brain tumors grow new blood vessels. Their article appeared in Molecular Neurobiology. Glioblastoma is a fast-growing, highly vascular brain tumor. Its growth depends on angiogenesis, the sprouting of new capillaries from existing vessels. The authors explain how signals from the tumor drive that sprouting.
The review sums up the growth factors and genes that push vessel growth in these tumors. It also covers the factors that hold the process back. Much of the focus falls on anti-angiogenesis therapy. Such treatment aims to slow the tumor by blocking its new blood supply. Readers get a clear picture of vessel growth as both a driver of the disease and a target for drugs.
Catalog record
| CREATOR | Ahir BK, Engelhard HH, Lakka SS. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 88 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma By Bhavesh K Ahir, Herbert H Engelhard, Sajani S Lakka Published in: Molecular Neurobiology DOI: 10.1007/s12035-020-01892-8 ABSTRACT Abstract Angiogenesis is the growth of new capillaries from the preexisting blood vessels. Glioblastoma (GBM) tumors are highly vascularized tumors, and glioma growth depends on the formation of new blood vessels. Angiogenesis is a complex process involving proliferation, migration, and differentiation of vascular endothelial cells (ECs) under the stimulation of specific signals. It is controlled by the balance between its promoting and inhibiting factors. Various angiogenic factors and genes have been identified that stimulate glioma angiogenesis. Therefore, attention has been directed to anti-angiogenesis therapy in which glioma proliferation is inhibited by inhibiting the formation of new tumor vessels using angiogenesis inhibitory factors and drugs. Here, in this review, we highlight and summarize the various molecular mediators that regulate GBM angiogenesis with focus on recent clinical research on the potential of exploiting angiogenic pathways as a strategy in the treatment of GBM patients. Keywords: Angiogenesis, Anti-angiogenesis therapy, Glioblastoma (GBM), Clinical trials in glioblastoma (GBM), Tumor development INTRODUCTION Gliomas arising from the glial cells in the central nervous system of adult brain are the most common primary intracranial tumors and account for 70–80% of all brain tumors [1–3]. Based on the recent classification of central nervous system tumors, diffuse gliomas are categorized into four grades (I–IV) according to World Health Organization (WHO): diffuse astrocytoma (IDH mutant, WHO grade II), oligodendroglioma (IDH mutant, WHO grade II), oligoastrocytoma (IDH mutant, WHO grade II), anaplastic astrocytoma, anaplastic oligodendroglioma (IDH mutant, WHO grade II), oligoastrocytoma (IDH mutant, WHO grade III), and glioblastoma multiforme (GBM or IDH mutant WHO grade IV) [4–6]. Furthermore, among all glioma cases diagnosed, astrocytoma grade III and GBM is considered to be the most aggressive and highly invasive as they spread into other parts of the brain quickly [7]. In spite of the aggressive treatments that include surgery combined with radiation, chemotherapy [8], and biological therapy [9], glioblastoma tumors remain as an enormous therapeutic challenge with survival rates following diagnosis of 12 to 15 months with less than 3 to 5% of people surviving longer than 5 years [10]. GBM tumors are also highly vascular brain tumors with very poor prognosis [11, 12]. Several angiogenic receptors and factors are upregulated in GBM and stimulate angiogenesis signaling pathways through activating oncogenes and/or downregulating tumor suppressor genes [13]. In this review, we will review the basic mechanisms of various molecular signaling events that regulate GBM angiogenesis and explore the potential of targeting angiogenic signaling as a therapeutic strategy for brain tumor pathogenesis. ANGIOGENESIS IN NORMAL PHYSIOLOGY AND IN TUMOR PROGRESSION Physiological angiogenesis is a highly regulated process and is an essential one for the adequate supply of nutrients and oxygen to developing or healing tissues [14]. It is composed of many steps and is a combination of various components such as cells (endothelial cells and mural cells), soluble growth factors, proteolytic enzymes and adhesion proteins and matrix components (ECM) as shown in Fig. 1 [15, 16]. Hypoxia (low oxygen tension) is the main trigger which induce the activation of transcription factor, hypoxia-inducible factor-1 (HIF-1), which controls the expression of growth factors [17], matrix components [18, 19], adhesion molecules [20], and metabolic proteins [21]. The induction of angiogenesis relies on a balance between pro- and anti-angiogenic factors. Lack of oxygen in the cell simulates the release of pro-angiogenic growth factors like vascular endothelial growth factor (VEGF) [22], transforming growth factor-β (TGF-β) [23], fibroblast growth factors (FGFs) [24], angiopoietin-1 [25], and epidermal growth factor (EGF) [26]. These angiogenic factors bind to their receptors on the endothelial cell membrane resulting in the dissolution of the vessel wall and degradation of the endothelial cell basement membrane and extracellular matrix (ECM). Following the degradation of the basement membrane, specific proteases such as matrix metalloproteinases (MMPs) remodel the extracellular matrix components and a new matrix is synthesized by stromal cells which in turn foster the migration and proliferation of endothelial cells resulting in the formation of an endothelial tube-like structure [27]. Finally, a mature vascular basement membrane is formed around this newly formed the endothelial tube and the Mural cells (pericytes and smooth muscle cells) surrounding it resulting in a stable new vessel (Fig. 1) [28, 29]. [Figure: Schematic representation of angiogenic events in GBM. (a) Angiogenesis processes are initiated by the angiogenic factors, which are being released from the GBM cells in the hypoxic tumor microenvironment. The major angiogenic factors are involved in GBM angiogenesis process which includes the VEGF, FGF, HIF1α, and Ang-1 and Ang-2. (b) These angiogenic factors bind to their receptors on endothelial cells and then start to initiate the endothelial cell proliferation and migration. During the endothelial cell proliferation and migration processes, the ECM start to degrade, and the endothelial cells are assembled into a tube/vessel-like structure. (c) The final step of GBM angiogenesis process is the maturation of the blood vessel wall, which is constructed by the recruitment of pericytes to cover the endothelial cells from its outside to form a new blood vessel formation] Angiogenesis is essential for tumor growth and progression. The tumor cells away from vessels experience hypoxia due to deficiency of blood and oxygen. Hypoxic environment induces cancer stem cells (CSCs) to differentiate toward endothelial progenitor cells and mature endothelium, which in turn generates new blood vessels inside the tumor. Tumors generate abnormal and functionally immature blood vessels due to deregulated factors such angiogenic growth factors, angiogenesis inhibitors, and other genetic factors by a process known as pathological angiogenesis [30]. Blood vessels developing in the primary tumor are larger than their normal counterparts and follow a criss-cross path, with irregular lumen diameters, dilated, highly permeable, and branch irregularly [31]. The tumor vasculature is also hyperpermeable to plasma and plasma proteins leading to local edema and extravascular clotting of plasma [32, 33]. This increase in the interstitial pressure in the tumor vasculature alters the blood flow and flux of leukocytes reaching the tumor site [34]. In addition, tumor cells can easily spread to the distant tissues due to the defective basement membrane and lack of normal perivascular connective tissue barrier [35]. Leakiness and compression of vessels leaves large volumes of tissue without blood flow in tumor and obstructs the delivery of blood-borne drugs, oxygen, and nutrients resulting in ischemia and necrotic regions within the tumor [36–38]. Ischemia leads to a hypoxic environment which in turn activates the HIF-1 resulting in new blood vessel formation [39]. Thus, the disorderly grown tumor vasculature observed in the tumors dramatically alters the tumor microenvironment and influences various aspects of tumor progression like tumor growth, allows easy penetration of the tumor cells and its ability to metastasize to distant sites, escape from the host immune system and response to anticancer therapies. Given the role of angiogenesis in tumor growth, targeting tumor vasculature and inhibition of growth factors/signaling pathways necessary for endothelial cell growth and proliferation is one of the practical approaches to inhibit tumor angiogenesis. FACTORS INVOLVED IN BRAIN TUMOR ANGIOGENESIS Brain tumor progression is closely associated with the formation of new vessels. Brain tumor angiogenesis is mediated through the action of many angiogenic factors, some of which are involved